No abstract

No abstract

In 2019, the Veterans Affairs (VA), the largest integrated US healthcare system, started the Pharmacogenomic Testing for Veterans (PHASER) clinical program that provides multi-gene pharmacogenomic (PGx) testing for up to 250,000 veterans at approximately 50 sites. PHASER is staggering program initiation at sites over a 5-year period from 2019 to 2023, as opposed to simultaneous initiation at all sites, to facilitate iterative program quality improvements through Plan-Do-Study-Act cycles. Current resources in the PGx field have not focused on multisite, remote implementation of panel-based PGx testing. In addition to bringing large scale PGx testing to veterans, the PHASER program is developing a roadmap to maximize uptake and optimize the use of PGx to improve drug response outcomes.

Abstract. We study trust and context as factors influencing how people choose wireless network names. Our approach imagines the mindset of a hypothetical attacker whose goal is to ensnare unsuspecting victims into accessing dishonest WiFi access points. For this purpose, we conducted an online survey. We used two separate forms. The first form asked a random group of participants to rate a list of wireless names according to their preferences (some real and others purposely made-up) and afterwards with implied trust in mind. The second form was designed to assess the effect of context and it asked a different set of respondents to rate the same list of wireless names in relation to four different contexts. Our results provide some evidence confirming the idea that trust and context can be exploited by an attacker by purposely, or strategically, naming WiFi access points with reference to trust or within certain contexts. We suggest, in certain cases, possible defence strategies.

Aim: The first Plan-Do-Study-Act cycle for the Veterans Affairs Pharmacogenomic Testing for Veterans pharmacogenomic clinical testing program is described. Materials & methods: Surveys evaluating implementation resources and processes were distributed to implementation teams, providers, laboratory and health informatics staff. Survey responses were mapped to the Consolidated Framework for Implementation Research constructs to identify implementation barriers. The Expert Recommendation for Implementing Change strategies were used to address implementation barriers. Results: Survey response rate was 23–73% across personnel groups at six Veterans Affairs sites. Nine Consolidated Framework for Implementation Research constructs were most salient implementation barriers. Program revisions addressed these barriers using the Expert Recommendation for Implementing Change strategies related to three domains. Conclusion: Beyond providing free pharmacogenomic testing, additional implementation barriers need to be addressed for improved program uptake.